[Nilestriol prevents osteoporosis in ovariectomized rats].
In order to determine the effects and mechanism of Nilestriol upon bone metabolism, 4-month aged female SD rats were divided randomly into three groups: The OVX group subjected to bilateral ovariectomy, the SHAM group to sham operation, the Nilestriol (CEE3) group to bilateral ovariectomy and treated with CEE3 0.15 mg/100 g BW once a week for 10 weeks. The CEE3 was introduced directly into the stomach from the first day after operation. All rats were killed 10 weeks after operation and their right proximal tibiae were processed undercalcified for quantitative bone histomorphometry. The weights of bone and inorganic matter (ash content) and content of calcium, phosphorus of right humeral were measured. The results showed that in the OVX group the trabecular bone volume, the trabecular thickness, the content of calcium bone, and the ratios of bone weight and ash weight to body weight were all significantly reduced. The bone loss was associated with an increase in bone remodeling; the bone resorption appeared much more marked than the bone formation. In contrast, the ovariectomized animals treated with CEE3 had normalization of bone mass and a declined index of bone resorption and formation which recovered the balance of bone remodeling. It suggested that CEE3 is successful in prevention of bone loss in OVX rats. It is convinced of using Nilestriol to prevent postmenopausal osteoporosis.
Liu
H
H
Yang
S
S
Xu
K
K
Li
H
H
Tan
J
J
D000818:Animals; D015519:Bone Density; D045166:Estradiol Congeners / Q000627:therapeutic use*; D015914:Estrogen Replacement Therapy; D005260:Female; D006801:Humans; D015663:Osteoporosis, Postmenopausal / Q000517:prevention & control*; D010052:Ovariectomy; D011800:Quinestrol / Q000031:analogs & derivatives* / Q000627:therapeutic use; D051381:Rats; D017207:Rats, Sprague-Dawley; D013977:Tibia / Q000648:ultrastructure
D045166:Estradiol Congeners; C010722:nylestriol; D011800:Quinestrol